Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 66.8383
- Book/Share 17.8792
- PB 18.4162
- Debt/Equity 5.6749
- CurrentRatio 1.2797
- ROIC 0.1044
- MktCap 177303645858.0
- FreeCF/Share 21.448
- PFCF 15.3656
- PE 25.2884
- Debt/Assets 0.6056
- DivYield 0.0289
- ROE 0.9619
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMGN | UBS | -- | Buy | -- | $380 | Jan. 7, 2026 |
| Upgrade | AMGN | Erste Group | Hold | Buy | -- | -- | Dec. 5, 2025 |
| Resumed | AMGN | Truist | -- | Hold | -- | $318 | Nov. 24, 2025 |
| Initiation | AMGN | Scotiabank | -- | Sector Outperform | -- | $385 | Nov. 13, 2025 |
| Resumed | AMGN | Raymond James | -- | Market Perform | -- | -- | Sept. 3, 2025 |
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
| Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
News
Healthy Returns: What to expect from pharma at the JPM conference
Published: January 09, 2026 by: CNBC
Sentiment: Positive
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Read More
Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd.
Read More
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
Read More
Can Amgen's MariTide Take on Leaders in the Obesity Space?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: December 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Can Amgen Sustain Its Rally In 2026
Published: December 26, 2025 by: Seeking Alpha
Sentiment: Positive
Amgen Inc. ends 2025 on a high note. Thanks to strong sales of Repatha and Imdelltra, it raised its full-year 2025 revenue guidance from $35-$36 billion to $35.8-$36.6 billion. So, sales of Repatha, a cholesterol-lowering medication, were $794 million in Q3, up 40% YoY.
Read More
Dogs of the Dow Beat the Market in 2025 — Here's the Smarter 4-Stock Play for 2026
Published: December 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
Keeping things simple when investing is often best, which is why buying an index fund can be the optimal strategy.
Read More
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
Read More
5 Big Drug Stocks That May Continue to Outperform in 2026
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
Read More
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
Published: December 19, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
Read More
AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
Published: December 19, 2025 by: PRNewsWire
Sentiment: Neutral
Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif. , Dec. 19, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while reinforcing Amgen's long-standing commitment to innovation.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
3 Healthcare Giants Just Raised Dividends—Here's Who Pays the Most
Published: December 16, 2025 by: MarketBeat
Sentiment: Positive
Major players in healthcare are increasing their commitments to return capital to shareholders, resulting in significantly higher dividends. Recent dividend announcements from major companies in the sector highlight evolving capital return strategies.
Read More
FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease
Published: December 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
New York, Dec. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. This is the first and only CD19-Targeted B-Cell therapy approved for gMG. The approval offers patients a new treatment option that has the potential for long-term disease control with just two doses a year, after two initial loading doses. Read the Amgen press release here.
Read More
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
Read More
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Published: December 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Why Is Amgen (AMGN) Up 8% Since Last Earnings Report?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
Read More
AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.
Read More
Here's Why Amgen (AMGN) is a Strong Momentum Stock
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
There Are Non-AI Stocks Worth Buying. Start With This List.
Published: November 12, 2025 by: Barrons
Sentiment: Positive
Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Amgen Stock: New All-Time Highs Ahead After Earnings Beat
Published: November 07, 2025 by: MarketBeat
Sentiment: Positive
Amgen Inc. NASDAQ: AMGN just delivered a strong beat-and-raise quarter. That's pushed the stock to within striking distance of its 52-week high.
Read More
Stock Of The Day: Will Amgen Reverse Again?
Published: November 06, 2025 by: Benzinga
Sentiment: Neutral
Amgen Inc. (NASDAQ:AMGN) is lower on Thursday. Yesterday, the shares gained almost 8% after the company released earnings.
Read More
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
Read More
Amgen: Q3 Earnings Indicate Strong Emphasis On R&D
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Positive
Amgen remains a compelling long-term buy, supported by robust R&D investment and a promising drug pipeline for future growth. AMGN delivered strong Q3 results, with double-digit revenue and volume growth across key segments, and maintains an attractive 3.2% dividend yield. Valuation metrics remain favorable, and management's focus on R&D and operating margins positions AMGN to capture expanding therapeutic markets.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000